Protagonist Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Protagonist Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||||||||||||||||
| current assets: | |||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 168,543,000 | 139,653,000 | 97,249,000 | 131,121,000 | 355,643,000 | 172,568,000 | 186,727,000 | 230,527,000 | 235,382,000 | 127,686,000 | 125,744,000 | 152,816,000 | 120,237,000 | 98,477,000 | 123,665,000 | 120,542,000 | 192,412,000 | 83,000,000 | 117,358,000 | 83,625,000 | 146,242,000 | 60,215,000 | 33,006,000 | 50,195,000 | 71,143,000 | 70,077,000 | 82,233,000 | 87,427,000 | 63,864,000 | 69,577,000 | 50,395,000 | 10,365,000 | 9,517,000 | 21,084,000 | 96,024,000 | 13,768,000 | |
| marketable securities | 401,922,000 | 434,707,000 | 321,664,000 | 337,600,000 | 208,354,000 | 150,067,000 | 154,890,000 | 90,224,000 | 78,019,000 | 103,073,000 | 111,611,000 | 114,621,000 | 171,653,000 | 206,812,000 | 203,235,000 | 193,759,000 | 161,868,000 | 190,476,000 | 188,451,000 | 110,349,000 | 62,423,000 | 57,298,000 | 100,011,000 | ||||||||||||||
| receivable from collaboration partner | 165,000,000 | 43,000 | 300,043,000 | 10,000,000 | 39,000 | 51,000 | |||||||||||||||||||||||||||||||
| contract asset | 23,363,000 | 22,825,000 | |||||||||||||||||||||||||||||||||||
| prepaid expenses and other current assets | 8,698,000 | 8,675,000 | 7,728,000 | 8,048,000 | 6,885,000 | 4,875,000 | 3,960,000 | 4,130,000 | 3,501,000 | 4,926,000 | 5,712,000 | 9,055,000 | 9,721,000 | 8,205,000 | 9,478,000 | 8,877,000 | 7,683,000 | 6,213,000 | 6,277,000 | 6,843,000 | 5,518,000 | 4,716,000 | 5,529,000 | 4,203,000 | 4,899,000 | 3,502,000 | 2,624,000 | 3,234,000 | 2,959,000 | 2,621,000 | 2,703,000 | 1,743,000 | 1,810,000 | 3,394,000 | 1,768,000 | 487,000 | |
| total current assets | 602,526,000 | 605,860,000 | 591,641,000 | 476,769,000 | 570,925,000 | 627,553,000 | 355,577,000 | 324,881,000 | 316,941,000 | 235,736,000 | 243,077,000 | 276,617,000 | 304,302,000 | 341,522,000 | 340,736,000 | 327,687,000 | 371,818,000 | 285,508,000 | 315,606,000 | 204,151,000 | 217,466,000 | 125,986,000 | 145,311,000 | 144,023,000 | 137,320,000 | 122,995,000 | 137,503,000 | 147,502,000 | 136,111,000 | 142,231,000 | 97,704,000 | 69,126,000 | 67,548,000 | 83,244,000 | 102,245,000 | 22,417,000 | |
| marketable securities - noncurrent | 102,493,000 | 123,517,000 | 140,252,000 | 114,560,000 | 31,447,000 | 1,985,000 | 38,169,000 | 26,122,000 | 6,254,000 | 2,000,000 | 6,025,000 | ||||||||||||||||||||||||||
| property and equipment | 4,108,000 | 3,530,000 | 3,190,000 | 2,468,000 | 1,780,000 | 1,111,000 | 1,195,000 | 1,421,000 | 1,263,000 | 1,341,000 | 1,565,000 | 1,783,000 | 1,962,000 | 2,064,000 | 1,798,000 | 1,723,000 | 1,718,000 | 1,432,000 | 1,462,000 | 1,459,000 | 1,553,000 | 1,603,000 | 1,681,000 | 1,734,000 | 1,692,000 | 1,546,000 | 861,000 | 904,000 | 912,000 | 1,001,000 | 945,000 | 903,000 | 641,000 | 562,000 | 564,000 | 599,000 | |
| restricted cash - noncurrent | 290,000 | 225,000 | 225,000 | 225,000 | 225,000 | 225,000 | 225,000 | 225,000 | 225,000 | 225,000 | 225,000 | 225,000 | 225,000 | 225,000 | 225,000 | 225,000 | 225,000 | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | |||||
| operating lease right-of-use asset | 8,589,000 | 9,000,000 | 9,417,000 | 9,835,000 | 10,252,000 | 387,000 | 954,000 | 1,504,000 | 2,037,000 | 2,556,000 | 3,061,000 | 3,549,000 | 4,023,000 | 4,485,000 | 4,936,000 | 5,371,000 | 4,349,000 | 4,653,000 | 4,950,000 | 5,235,000 | 5,511,000 | 5,780,000 | 6,042,000 | 6,295,000 | 6,539,000 | 6,779,000 | |||||||||||
| total assets | 718,006,000 | 742,132,000 | 744,725,000 | 603,857,000 | 614,629,000 | 629,276,000 | 357,951,000 | 330,016,000 | 320,466,000 | 239,858,000 | 247,928,000 | 282,174,000 | 310,512,000 | 348,296,000 | 347,695,000 | 373,175,000 | 404,232,000 | 298,072,000 | 324,468,000 | 217,320,000 | 224,980,000 | 134,901,000 | 154,917,000 | 154,627,000 | 148,105,000 | 132,248,000 | 139,472,000 | 148,856,000 | 137,473,000 | 149,239,000 | 163,734,000 | 110,415,000 | 70,479,000 | 82,673,000 | 93,990,000 | 102,843,000 | 24,516,000 |
| liabilities and stockholders’ equity | |||||||||||||||||||||||||||||||||||||
| current liabilities: | |||||||||||||||||||||||||||||||||||||
| accounts payable | 3,249,000 | 2,917,000 | 1,615,000 | 3,049,000 | 3,629,000 | 3,507,000 | 772,000 | 1,252,000 | 4,573,000 | 4,021,000 | 3,640,000 | 4,715,000 | 1,412,000 | 7,159,000 | 1,600,000 | 706,000 | 7,905,000 | 2,732,000 | 3,075,000 | 2,797,000 | 2,855,000 | 3,704,000 | 2,790,000 | 1,583,000 | 2,787,000 | 6,454,000 | 5,711,000 | 4,871,000 | 2,278,000 | 1,307,000 | 2,267,000 | 2,639,000 | 1,132,000 | 1,163,000 | 2,335,000 | 1,441,000 | |
| accrued expenses and other payables | 15,397,000 | 11,843,000 | 23,693,000 | 20,739,000 | 15,175,000 | 16,487,000 | 19,358,000 | 24,809,000 | 19,369,000 | 16,587,000 | 24,955,000 | 29,574,000 | 36,244,000 | 32,874,000 | 37,716,000 | 33,061,000 | 20,096,000 | 17,680,000 | 18,498,000 | 15,518,000 | 12,917,000 | 11,616,000 | 12,360,000 | 10,486,000 | 10,845,000 | 8,713,000 | 11,163,000 | 10,496,000 | 13,262,000 | 10,358,000 | 8,241,000 | 6,727,000 | 6,647,000 | 5,272,000 | 3,014,000 | 2,669,000 | |
| income taxes payable | 1,889,000 | 2,689,000 | 1,049,000 | 2,650,000 | 3,326,000 | ||||||||||||||||||||||||||||||||
| deferred revenue | 14,688,000 | 16,895,000 | 18,891,000 | 19,696,000 | |||||||||||||||||||||||||||||||||
| operating lease liability | 2,173,000 | 1,568,000 | 510,000 | 45,000 | |||||||||||||||||||||||||||||||||
| total current liabilities | 35,507,000 | 35,112,000 | 47,398,000 | 44,578,000 | 41,578,000 | 39,910,000 | 21,274,000 | 27,867,000 | 26,398,000 | 23,229,000 | 31,179,000 | 36,754,000 | 40,088,000 | 43,456,000 | 44,016,000 | 39,156,000 | 42,973,000 | 34,515,000 | 40,241,000 | 38,563,000 | 35,360,000 | 36,372,000 | 35,406,000 | 30,776,000 | 33,323,000 | 24,499,000 | 26,158,000 | 24,101,000 | 29,018,000 | 33,924,000 | 52,247,000 | 9,366,000 | 7,779,000 | 6,435,000 | 5,349,000 | 4,110,000 | |
| deferred revenue - noncurrent | 5,375,000 | 8,176,000 | 11,676,000 | 16,509,000 | 20,756,000 | 28,922,000 | |||||||||||||||||||||||||||||||
| operating lease liability - noncurrent | 9,106,000 | 9,792,000 | 10,356,000 | 10,855,000 | 10,971,000 | 462,000 | 1,804,000 | 2,446,000 | 3,062,000 | 3,658,000 | 4,238,000 | 3,691,000 | 4,102,000 | 4,500,000 | 4,885,000 | 5,259,000 | 5,616,000 | 5,961,000 | 6,293,000 | 6,616,000 | 6,924,000 | ||||||||||||||||
| total liabilities | 49,988,000 | 53,080,000 | 69,430,000 | 71,942,000 | 73,305,000 | 68,832,000 | 21,274,000 | 27,867,000 | 26,398,000 | 23,691,000 | 32,320,000 | 38,558,000 | 42,534,000 | 46,518,000 | 47,674,000 | 43,515,000 | 46,785,000 | 38,738,000 | 44,862,000 | 47,730,000 | 57,495,000 | 72,235,000 | 74,953,000 | 59,269,000 | 63,789,000 | 31,423,000 | 26,957,000 | 24,898,000 | 29,811,000 | 34,618,000 | 52,579,000 | 9,449,000 | 6,435,000 | 5,349,000 | 4,110,000 | ||
| commitments and contingencies | |||||||||||||||||||||||||||||||||||||
| stockholders’ equity: | |||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding | |||||||||||||||||||||||||||||||||||||
| common stock | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | |||||||||||||||||||||||||||
| additional paid-in capital | 1,054,980,000 | 1,041,143,000 | 1,015,898,000 | 1,002,774,000 | 980,558,000 | 969,042,000 | 952,491,000 | 945,363,000 | 903,205,000 | 786,768,000 | 752,722,000 | 746,657,000 | 740,027,000 | 732,542,000 | 709,682,000 | 702,319,000 | 696,157,000 | 567,176,000 | 563,389,000 | 434,603,000 | 424,855,000 | 300,300,000 | 297,846,000 | 295,672,000 | 268,234,000 | 255,591,000 | 253,222,000 | 250,670,000 | 225,622,000 | 223,904,000 | 156,234,000 | 154,700,000 | 153,610,000 | 152,393,000 | 150,863,000 | 158,000 | |
| accumulated other comprehensive loss | -15,000 | -82,000 | -249,000 | -229,000 | -105,000 | -170,000 | -198,000 | -122,000 | -359,000 | -480,000 | -720,000 | -472,000 | -88,000 | -208,000 | -221,000 | -154,000 | -167,000 | -189,000 | -233,000 | -103,000 | -86,000 | -72,000 | -22,000 | -245,000 | -24,000 | -101,000 | |||||||||||
| accumulated deficit | -386,948,000 | -352,177,000 | -340,522,000 | -472,196,000 | -438,986,000 | -408,370,000 | -615,710,000 | -643,045,000 | -608,940,000 | -570,480,000 | -536,755,000 | -502,561,000 | -471,329,000 | -430,292,000 | -409,362,000 | -372,455,000 | -338,651,000 | -307,809,000 | -283,811,000 | -264,925,000 | -257,162,000 | -237,741,000 | -217,661,000 | -200,160,000 | -183,751,000 | -154,577,000 | -140,474,000 | -126,609,000 | -117,874,000 | -109,211,000 | -101,550,000 | -98,498,000 | -93,673,000 | -78,694,000 | -64,593,000 | -53,345,000 | -46,261,000 |
| total stockholders’ equity | 668,018,000 | 689,052,000 | 675,295,000 | 531,915,000 | 541,324,000 | 560,444,000 | 336,677,000 | 302,149,000 | 294,068,000 | 216,167,000 | 215,608,000 | 243,616,000 | 267,978,000 | 301,778,000 | 300,021,000 | 329,660,000 | 357,447,000 | 259,334,000 | 279,606,000 | 169,590,000 | 167,485,000 | 62,666,000 | 79,964,000 | 95,358,000 | 84,316,000 | 100,825,000 | 112,515,000 | 123,958,000 | 107,662,000 | 114,621,000 | 120,632,000 | 57,836,000 | 61,030,000 | 74,894,000 | 87,555,000 | 97,494,000 | |
| total liabilities and stockholders’ equity | 718,006,000 | 742,132,000 | 744,725,000 | 603,857,000 | 614,629,000 | 629,276,000 | 357,951,000 | 330,016,000 | 320,466,000 | 239,858,000 | 247,928,000 | 282,174,000 | 310,512,000 | 348,296,000 | 347,695,000 | 373,175,000 | 404,232,000 | 298,072,000 | 324,468,000 | 217,320,000 | 224,980,000 | 134,901,000 | 154,917,000 | 154,627,000 | 148,105,000 | 132,248,000 | 139,472,000 | 148,856,000 | 137,473,000 | 149,239,000 | 70,479,000 | 82,673,000 | |||||
| accumulated other comprehensive income | 85,000 | 1,336,000 | |||||||||||||||||||||||||||||||||||
| payable to collaboration partner | 3,000 | 3,000 | 3,000 | 10,000 | 22,000 | ||||||||||||||||||||||||||||||||
| deferred revenue - current | 20,124,000 | 16,125,000 | |||||||||||||||||||||||||||||||||||
| operating lease liability - current | 462,000 | 1,141,000 | 1,803,000 | 2,446,000 | 2,599,000 | 2,433,000 | 2,352,000 | 2,275,000 | 2,200,000 | 2,027,000 | 1,567,000 | 1,512,000 | 1,459,000 | 1,406,000 | 1,355,000 | 1,306,000 | 1,256,000 | 1,209,000 | 1,164,000 | 1,120,000 | |||||||||||||||||
| receivable from collaboration partner – related party | 10,000 | ||||||||||||||||||||||||||||||||||||
| research and development tax incentive receivable | 2,648,000 | 2,878,000 | 2,792,000 | 1,871,000 | 2,778,000 | 1,823,000 | 1,084,000 | 535,000 | 276,000 | 153,000 | 173,000 | 1,421,000 | 1,876,000 | 1,429,000 | 1,155,000 | 2,190,000 | 1,918,000 | 885,000 | 2,881,000 | 2,480,000 | 2,241,000 | 1,944,000 | 1,744,000 | ||||||||||||||
| restricted cash – noncurrent | 225,000 | ||||||||||||||||||||||||||||||||||||
| payable to collaboration partner – related party | 69,000 | ||||||||||||||||||||||||||||||||||||
| deferred revenue – related party | |||||||||||||||||||||||||||||||||||||
| operating lease liability – current | 2,515,000 | ||||||||||||||||||||||||||||||||||||
| operating lease liability – noncurrent | 1,141,000 | ||||||||||||||||||||||||||||||||||||
| receivable from collaboration partner and contract asset - related party | 125,000 | 43,000 | 25,150,000 | 1,566,000 | 2,638,000 | 7,077,000 | 3,996,000 | 2,426,000 | 2,789,000 | 2,997,000 | 3,594,000 | 6,755,000 | 1,945,000 | 4,889,000 | 5,061,000 | 4,587,000 | |||||||||||||||||||||
| payable to collaboration partner - related party | 32,000 | 80,000 | 380,000 | 899,000 | 1,121,000 | 11,396,000 | 6,823,000 | 2,732,000 | 2,077,000 | 1,003,000 | 1,116,000 | 1,262,000 | 1,020,000 | 810,000 | 1,211,000 | 1,061,000 | 764,000 | 276,000 | 379,000 | ||||||||||||||||||
| deferred revenue - related party | 768,000 | 1,601,000 | 2,241,000 | 2,009,000 | 16,478,000 | 17,717,000 | 7,001,000 | 8,223,000 | 7,970,000 | 13,202,000 | 21,880,000 | 31,752,000 | 41,739,000 | ||||||||||||||||||||||||
| restricted cash - current | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | |||||||||||||||||||||||||
| other liabilities | 121,000 | 121,000 | 121,000 | 121,000 | |||||||||||||||||||||||||||||||||
| accumulated other comprehensive gain | -299,000 | -204,000 | -59,000 | -33,000 | 28,000 | 107,000 | 100,000 | 3,000 | |||||||||||||||||||||||||||||
| deferred revenue - related party - current | 5,768,000 | 14,477,000 | 16,765,000 | 17,230,000 | 18,630,000 | 17,738,000 | |||||||||||||||||||||||||||||||
| deferred tax asset | 1,082,000 | 1,433,000 | 2,125,000 | 2,104,000 | 478,000 | ||||||||||||||||||||||||||||||||
| long-term debt | 9,832,000 | 9,794,000 | |||||||||||||||||||||||||||||||||||
| deferred revenue - related party - noncurrent | 4,112,000 | 16,784,000 | 20,415,000 | 23,792,000 | 22,200,000 | 23,850,000 | |||||||||||||||||||||||||||||||
| other liability - noncurrent | 170,000 | 92,000 | |||||||||||||||||||||||||||||||||||
| deferred rent | 83,000 | ||||||||||||||||||||||||||||||||||||
| available-for-sale securities | 87,497,000 | 54,958,000 | 42,469,000 | 51,090,000 | 61,303,000 | 65,383,000 | 2,499,000 | 6,408,000 | |||||||||||||||||||||||||||||
| available-for-sale securities - current | 46,620,000 | 43,191,000 | 54,127,000 | 53,731,000 | 56,515,000 | ||||||||||||||||||||||||||||||||
| available-for-sale securities - noncurrent | 5,557,000 | 11,316,000 | 14,000,000 | 10,150,000 | |||||||||||||||||||||||||||||||||
| deferred tax asset - noncurrent | 658,000 | ||||||||||||||||||||||||||||||||||||
| deferred rent - noncurrent | 799,000 | 797,000 | 793,000 | 694,000 | 332,000 | ||||||||||||||||||||||||||||||||
| restricted cash | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | |||||||||||||||||||||||||||||||
| receivable from collaboration partner - related party | 4,586,000 | 5,785,000 | 2,722,000 | 520,000 | |||||||||||||||||||||||||||||||||
| consolidated balance sheet data: | |||||||||||||||||||||||||||||||||||||
| cash, cash equivalents and available-for-sale securities | 155,459,000 | ||||||||||||||||||||||||||||||||||||
| working capital | 108,392,000 | ||||||||||||||||||||||||||||||||||||
| redeemable convertible preferred stock | |||||||||||||||||||||||||||||||||||||
| other assets | 34,000 | 34,000 | 34,000 | 34,000 | |||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value, 10,000,000 shares authorized; and no shares issued and outstanding as of september 30, 2017 and december 31, 2016 | |||||||||||||||||||||||||||||||||||||
| total liabilities and stockholders' equity | 110,415,000 | ||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value, 10,000,000 shares authorized; and no shares issued and outstanding as of june 30, 2017 and december 31, 2016 | |||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value, 10,000,000 shares authorized; and no shares issued and outstanding as of march 31, 2017 (unaudited) and december 31, 2016 | |||||||||||||||||||||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ equity | |||||||||||||||||||||||||||||||||||||
| stockholders’ equity | |||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value, 10,000,000 and no shares authorized as of december 31, 2016 and 2015, respectively; and no shares issued and outstanding as of december 31, 2016 and 2015 | |||||||||||||||||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ equity | 93,990,000 | 102,843,000 | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value, 10,000,000 and 0 shares authorized as of september 30, 2016 (unaudited) and december 31, 2015, respectively; and no shares issued and outstanding as of september 30, 2016 (unaudited) and december 31, 2015 | |||||||||||||||||||||||||||||||||||||
| deferred offering costs | 1,466,000 | ||||||||||||||||||||||||||||||||||||
| liabilities redeemable convertible preferred stock and stockholders’ deficit | |||||||||||||||||||||||||||||||||||||
| stockholders’ deficit: | |||||||||||||||||||||||||||||||||||||
| total stockholders’ deficit | -46,204,000 | ||||||||||||||||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ deficit | 24,516,000 | ||||||||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||||
| research and development | 5,696,000 | ||||||||||||||||||||||||||||||||||||
| general and administrative | 1,395,000 | ||||||||||||||||||||||||||||||||||||
| total operating expenses | 7,091,000 | ||||||||||||||||||||||||||||||||||||
| income from operations | -7,091,000 | ||||||||||||||||||||||||||||||||||||
| interest income | 27,000 | ||||||||||||||||||||||||||||||||||||
| change in fair value of redeemable convertible preferred stock tranche and warrant liabilities | |||||||||||||||||||||||||||||||||||||
| other income | -34,000 | ||||||||||||||||||||||||||||||||||||
| net income | -7,098,000 | ||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -7,323,000 | ||||||||||||||||||||||||||||||||||||
| net income per share | -19,070 | ||||||||||||||||||||||||||||||||||||
| weighted-average shares used for eps calculation | 383,910,000 |
We provide you with 20 years of balance sheets for Protagonist Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Protagonist Therapeutics. Explore the full financial landscape of Protagonist Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Protagonist Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.